At Vetigenics, we harness the power of the dog’s own immune system to bring the latest advancements in biotechnology to improve animal health.
Vetigenics, founded by Nicola Mason BVetMD, PhD and Don Siegel PhD, MD both Professors at UPenn, have created the only comprehensive, canine single chain fragment variable (scFv) phage display libraries estimated to contain over 40 billion independent scFv members.
CANIBODIES™ are entirely canine scFvs uniquely selected from the library based on their antigen-binding capabilities, functionality and developability. As they are generated from native canine immunoglobulin germline genes, they do not require caninization or chimeric (mouse/canine) design and offer reduced immunogenicity when compared to antibodies generated by competitive methods.
Furthermore, as the library’s repertoire is not limited by central tolerance, CANIBODIES™ are highly versatile, can be rapidly, readily isolated and engineered into alternative therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs.
Working closely with a wide network of experts in animal and human health, Vetigenics is devoted advancing our portfolio of drug candidates to enhance and extend the lives of our cherished companions.
For more information contact:
Adriann Sax, CEO
asax@vetigenics.com
Vetigenics, founded by Nicola Mason BVetMD, PhD and Don Siegel PhD, MD both Professors at UPenn, have created the only comprehensive, canine single chain fragment variable (scFv) phage display libraries estimated to contain over 40 billion independent scFv members.
CANIBODIES™ are entirely canine scFvs uniquely selected from the library based on their antigen-binding capabilities, functionality and developability. As they are generated from native canine immunoglobulin germline genes, they do not require caninization or chimeric (mouse/canine) design and offer reduced immunogenicity when compared to antibodies generated by competitive methods.
Furthermore, as the library’s repertoire is not limited by central tolerance, CANIBODIES™ are highly versatile, can be rapidly, readily isolated and engineered into alternative therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs.
Working closely with a wide network of experts in animal and human health, Vetigenics is devoted advancing our portfolio of drug candidates to enhance and extend the lives of our cherished companions.
For more information contact:
Adriann Sax, CEO
asax@vetigenics.com
Location: United States, Pennsylvania, Philadelphia
Employees: 1-10
Total raised: $6M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 28.07.2021 | PCI Ventur... | pci.upenn.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.02.2025 | Seed | $6M | - |
Mentions in press and media 1
| Date | Title | Description |
| 03.02.2025 | Vetigenics Raises $6M in Seed Funding | Vetigenics, a Philadelphia, PA-based clinical-stage animal health biotechnology company, raised $6M in Seed funding. Backers were not disclosed. The company intends to use the funds to advance clinical-stage programs toward pivotal trials, ... |